Translator Disclaimer
22 February 2013 Effectiveness of tobramycin conjugated to iron oxide nanoparticles in treating infection in cystic fibrosis
Author Affiliations +
Cystic fibrosis (CF) is an inherited childhood-onset life-shortening disease. It is characterized by increased respiratory production, leading to airway obstruction, chronic lung infection and inflammatory reactions. The most common bacteria causing persisting infections in people with CF is Pseudomonas aeruginosa. Superparamagnetic Fe3O4 iron oxide nanoparticles (NPs) conjugated to the antibiotic (tobramycin), guided by a gradient of the magnetic field or subjected to an oscillating magnetic field, show promise in improving the drug delivery across the mucus and P. aeruginosa biofilm to the bacteria. The question remains whether tobramycin needs to be released from the NPs after the penetration of the mucus barrier in order to act upon the pathogenic bacteria. We used a zero-length 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) crosslinking agent to couple tobramycin, via its amine groups, to the carboxyl groups on Fe3O4 NPs capped with citric acid. The therapeutic efficiency of Fe3O4 NPs attached to the drug versus that of the free drug was investigated in P. aeruginosa culture.
© (2013) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Yekaterina I. Brandt, Leisha M. Armijo, Antonio C. Rivera, John B. Plumley, Nathaniel C. Cook, Gennady A. Smolyakov, Hugh D. C. Smyth, and Marek Osiński "Effectiveness of tobramycin conjugated to iron oxide nanoparticles in treating infection in cystic fibrosis", Proc. SPIE 8595, Colloidal Nanocrystals for Biomedical Applications VIII, 85951C (22 February 2013);

Back to Top